http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 25 Aug 2026 06:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arcturus+Therapeutics+++++For%3A+Aug+25/26970343.html si-local-file:///var/storage/secattach/20260825/26970343.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arcturus+Therapeutics+++++For%3A+Aug+25/26970343.html Tue, 25 Aug 2026 06:05:00 -0400 ARCT O.41325150 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arcturus+Therapeutics+++++For%3A+Aug+25/26970343.html si-local-file:///var/storage/secattach/20260825/26970343.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arcturus+Therapeutics+++++For%3A+Aug+25/26970343.html Tue, 25 Aug 2026 06:05:00 -0400 ARCT O.41325150 http://www.streetinsider.com/Earnings/Arcturus+Therapeutics+%28ARCT%29+Tops+Q2+EPS+by+21c/26885523.html <p>Arcturus Therapeutics (NASDAQ: ARCT) reported Q2 EPS of ($0.84), $0.21 better than the analyst estimate of ($1.05). Revenue for the quarter came in at $2.96 million.</p><p>For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) <a href="http://www.streetinsider.com/ec_earnings.php?q=ARCT">click here</a>.</p> http://www.streetinsider.com/Earnings/Arcturus+Therapeutics+%28ARCT%29+Tops+Q2+EPS+by+21c/26885523.html Thu, 06 Aug 2026 17:14:17 -0400 ARCT http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Arcturus+Therapeutics+++++For%3A+Jun+30/26884450.html si-local-file:///var/storage/secattach/20260806/26884450.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Arcturus+Therapeutics+++++For%3A+Jun+30/26884450.html Thu, 06 Aug 2026 16:20:00 -0400 ARCT O.41325150 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Arcturus+Therapeutics+++++For%3A+Jun+30/26884450.html si-local-file:///var/storage/secattach/20260806/26884450.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Arcturus+Therapeutics+++++For%3A+Jun+30/26884450.html Thu, 06 Aug 2026 16:20:00 -0400 ARCT O.41325150 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arcturus+Therapeutics+++++For%3A+Aug+06/26883697.html si-local-file:///var/storage/secattach/20260806/26883697.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arcturus+Therapeutics+++++For%3A+Aug+06/26883697.html Thu, 06 Aug 2026 16:06:00 -0400 ARCT O.41325150 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arcturus+Therapeutics+++++For%3A+Aug+06/26883697.html si-local-file:///var/storage/secattach/20260806/26883697.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arcturus+Therapeutics+++++For%3A+Aug+06/26883697.html Thu, 06 Aug 2026 16:06:00 -0400 ARCT O.41325150 http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Pipeline+Progress/26883266.html <p class="bwalignc"> <i>ARCT-032 (CF) Phase 2 study enrollment remains on schedule; the decision to proceed into Phase 3 expected Q4 2026</i> </p><p class="bwalignc"> <i>ARCT-810 (OTC Deficiency) Phase 2 study enrollment and dosing completed; data and regulatory plan to be communicated Q3 2026</i> </p><p class="bwalignc"> <i>Arcturus regains global rights to KOSTAIVE® and infectious disease portfolio; receives $12 million in cash and $16 million in released liabilities and R&amp;D credits</i> </p><p class="bwalignc"> Investor conference call at 4:30 p.m. ET today </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Pipeline+Progress/26883266.html Thu, 06 Aug 2026 16:01:00 -0400 A.28837022 ARCT O.05105684 O.41325150 http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Pipeline+Progress/26883266.html <p class="bwalignc"> <i>ARCT-032 (CF) Phase 2 study enrollment remains on schedule; the decision to proceed into Phase 3 expected Q4 2026</i> </p><p class="bwalignc"> <i>ARCT-810 (OTC Deficiency) Phase 2 study enrollment and dosing completed; data and regulatory plan to be communicated Q3 2026</i> </p><p class="bwalignc"> <i>Arcturus regains global rights to KOSTAIVE® and infectious disease portfolio; receives $12 million in cash and $16 million in released liabilities and R&amp;D credits</i> </p><p class="bwalignc"> Investor conference call at 4:30 p.m. ET today </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Pipeline+Progress/26883266.html Thu, 06 Aug 2026 16:01:00 -0400 A.28837022 ARCT O.05105684 O.41325150 http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Pipeline+Progress/26883266.html <p class="bwalignc"> <i>ARCT-032 (CF) Phase 2 study enrollment remains on schedule; the decision to proceed into Phase 3 expected Q4 2026</i> </p><p class="bwalignc"> <i>ARCT-810 (OTC Deficiency) Phase 2 study enrollment and dosing completed; data and regulatory plan to be communicated Q3 2026</i> </p><p class="bwalignc"> <i>Arcturus regains global rights to KOSTAIVE® and infectious disease portfolio; receives $12 million in cash and $16 million in released liabilities and R&amp;D credits</i> </p><p class="bwalignc"> Investor conference call at 4:30 p.m. ET today </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Pipeline+Progress/26883266.html Thu, 06 Aug 2026 16:01:00 -0400 A.28837022 ARCT O.05105684 O.41325150 http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Pipeline+Progress/26883266.html <p class="bwalignc"> <i>ARCT-032 (CF) Phase 2 study enrollment remains on schedule; the decision to proceed into Phase 3 expected Q4 2026</i> </p><p class="bwalignc"> <i>ARCT-810 (OTC Deficiency) Phase 2 study enrollment and dosing completed; data and regulatory plan to be communicated Q3 2026</i> </p><p class="bwalignc"> <i>Arcturus regains global rights to KOSTAIVE® and infectious disease portfolio; receives $12 million in cash and $16 million in released liabilities and R&amp;D credits</i> </p><p class="bwalignc"> Investor conference call at 4:30 p.m. ET today </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Pipeline+Progress/26883266.html Thu, 06 Aug 2026 16:01:00 -0400 A.28837022 ARCT O.05105684 O.41325150 http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Pipeline+Progress/26883266.html <p class="bwalignc"> <i>ARCT-032 (CF) Phase 2 study enrollment remains on schedule; the decision to proceed into Phase 3 expected Q4 2026</i> </p><p class="bwalignc"> <i>ARCT-810 (OTC Deficiency) Phase 2 study enrollment and dosing completed; data and regulatory plan to be communicated Q3 2026</i> </p><p class="bwalignc"> <i>Arcturus regains global rights to KOSTAIVE® and infectious disease portfolio; receives $12 million in cash and $16 million in released liabilities and R&amp;D credits</i> </p><p class="bwalignc"> Investor conference call at 4:30 p.m. ET today </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Pipeline+Progress/26883266.html Thu, 06 Aug 2026 16:01:00 -0400 A.28837022 ARCT O.05105684 O.41325150 http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Pipeline+Progress/26883266.html <p class="bwalignc"> <i>ARCT-032 (CF) Phase 2 study enrollment remains on schedule; the decision to proceed into Phase 3 expected Q4 2026</i> </p><p class="bwalignc"> <i>ARCT-810 (OTC Deficiency) Phase 2 study enrollment and dosing completed; data and regulatory plan to be communicated Q3 2026</i> </p><p class="bwalignc"> <i>Arcturus regains global rights to KOSTAIVE® and infectious disease portfolio; receives $12 million in cash and $16 million in released liabilities and R&amp;D credits</i> </p><p class="bwalignc"> Investor conference call at 4:30 p.m. ET today </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Pipeline+Progress/26883266.html Thu, 06 Aug 2026 16:01:00 -0400 A.28837022 ARCT O.05105684 O.41325150 http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Pipeline+Progress/26883266.html <p class="bwalignc"> <i>ARCT-032 (CF) Phase 2 study enrollment remains on schedule; the decision to proceed into Phase 3 expected Q4 2026</i> </p><p class="bwalignc"> <i>ARCT-810 (OTC Deficiency) Phase 2 study enrollment and dosing completed; data and regulatory plan to be communicated Q3 2026</i> </p><p class="bwalignc"> <i>Arcturus regains global rights to KOSTAIVE® and infectious disease portfolio; receives $12 million in cash and $16 million in released liabilities and R&amp;D credits</i> </p><p class="bwalignc"> Investor conference call at 4:30 p.m. ET today </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Pipeline+Progress/26883266.html Thu, 06 Aug 2026 16:01:00 -0400 A.28837022 ARCT O.05105684 O.41325150 http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Pipeline+Progress/26883266.html <p class="bwalignc"> <i>ARCT-032 (CF) Phase 2 study enrollment remains on schedule; the decision to proceed into Phase 3 expected Q4 2026</i> </p><p class="bwalignc"> <i>ARCT-810 (OTC Deficiency) Phase 2 study enrollment and dosing completed; data and regulatory plan to be communicated Q3 2026</i> </p><p class="bwalignc"> <i>Arcturus regains global rights to KOSTAIVE® and infectious disease portfolio; receives $12 million in cash and $16 million in released liabilities and R&amp;D credits</i> </p><p class="bwalignc"> Investor conference call at 4:30 p.m. ET today </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Pipeline+Progress/26883266.html Thu, 06 Aug 2026 16:01:00 -0400 A.28837022 ARCT O.05105684 O.41325150 http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+to+Report+Second+Quarter+Financial+Results+and+Provide+Corporate+Update+on+Aug+6%2C+2026/26826825.html <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended June 30, 2026, after the market close on Thursday, Aug 6th and will also host a conference call and webcast at 4:30 pm Eastern Time on Aug 6, 2026. </p><p> <b>Arcturus Therapeutics Second Quarter 2026 Earnings Conference Call</b> </p><ul class="bwlistdisc"> <li> Thursday, Aug 6, 2026, at 4:30 p.m. ET </li> <li> Domestic: 1-800-347-6865 </li> <li> International: 1-203-518-9757 </li> <li> Conference ID: ARCTURUS </li> <li> Webcast: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fviavid.webcasts.com%2Fstarthere.jsp%3Fei%3D1769554%26tp_key%3D96c7f551a6&amp;esheet=54578757&amp;newsitemid=20260728520662&amp;lan=en-US&amp;anchor=Link&amp;index=1&amp;md5=fe00d6b320171f46954ae91461348266" shape="rect">Link</a> </li> </ul><p> <b>About Arcturus</b> </p><p> Founded in 2013 http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+to+Report+Second+Quarter+Financial+Results+and+Provide+Corporate+Update+on+Aug+6%2C+2026/26826825.html Tue, 28 Jul 2026 16:01:00 -0400 ARCT O.41325150 http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+to+Report+Second+Quarter+Financial+Results+and+Provide+Corporate+Update+on+Aug+6%2C+2026/26826825.html <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended June 30, 2026, after the market close on Thursday, Aug 6th and will also host a conference call and webcast at 4:30 pm Eastern Time on Aug 6, 2026. </p><p> <b>Arcturus Therapeutics Second Quarter 2026 Earnings Conference Call</b> </p><ul class="bwlistdisc"> <li> Thursday, Aug 6, 2026, at 4:30 p.m. ET </li> <li> Domestic: 1-800-347-6865 </li> <li> International: 1-203-518-9757 </li> <li> Conference ID: ARCTURUS </li> <li> Webcast: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fviavid.webcasts.com%2Fstarthere.jsp%3Fei%3D1769554%26tp_key%3D96c7f551a6&amp;esheet=54578757&amp;newsitemid=20260728520662&amp;lan=en-US&amp;anchor=Link&amp;index=1&amp;md5=fe00d6b320171f46954ae91461348266" shape="rect">Link</a> </li> </ul><p> <b>About Arcturus</b> </p><p> Founded in 2013 http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+to+Report+Second+Quarter+Financial+Results+and+Provide+Corporate+Update+on+Aug+6%2C+2026/26826825.html Tue, 28 Jul 2026 16:01:00 -0400 ARCT O.41325150 http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+to+Report+Second+Quarter+Financial+Results+and+Provide+Corporate+Update+on+Aug+6%2C+2026/26826825.html <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended June 30, 2026, after the market close on Thursday, Aug 6th and will also host a conference call and webcast at 4:30 pm Eastern Time on Aug 6, 2026. </p><p> <b>Arcturus Therapeutics Second Quarter 2026 Earnings Conference Call</b> </p><ul class="bwlistdisc"> <li> Thursday, Aug 6, 2026, at 4:30 p.m. ET </li> <li> Domestic: 1-800-347-6865 </li> <li> International: 1-203-518-9757 </li> <li> Conference ID: ARCTURUS </li> <li> Webcast: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fviavid.webcasts.com%2Fstarthere.jsp%3Fei%3D1769554%26tp_key%3D96c7f551a6&amp;esheet=54578757&amp;newsitemid=20260728520662&amp;lan=en-US&amp;anchor=Link&amp;index=1&amp;md5=fe00d6b320171f46954ae91461348266" shape="rect">Link</a> </li> </ul><p> <b>About Arcturus</b> </p><p> Founded in 2013 http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+to+Report+Second+Quarter+Financial+Results+and+Provide+Corporate+Update+on+Aug+6%2C+2026/26826825.html Tue, 28 Jul 2026 16:01:00 -0400 ARCT O.41325150 http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+to+Report+Second+Quarter+Financial+Results+and+Provide+Corporate+Update+on+Aug+6%2C+2026/26826825.html <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended June 30, 2026, after the market close on Thursday, Aug 6th and will also host a conference call and webcast at 4:30 pm Eastern Time on Aug 6, 2026. </p><p> <b>Arcturus Therapeutics Second Quarter 2026 Earnings Conference Call</b> </p><ul class="bwlistdisc"> <li> Thursday, Aug 6, 2026, at 4:30 p.m. ET </li> <li> Domestic: 1-800-347-6865 </li> <li> International: 1-203-518-9757 </li> <li> Conference ID: ARCTURUS </li> <li> Webcast: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fviavid.webcasts.com%2Fstarthere.jsp%3Fei%3D1769554%26tp_key%3D96c7f551a6&amp;esheet=54578757&amp;newsitemid=20260728520662&amp;lan=en-US&amp;anchor=Link&amp;index=1&amp;md5=fe00d6b320171f46954ae91461348266" shape="rect">Link</a> </li> </ul><p> <b>About Arcturus</b> </p><p> Founded in 2013 http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+to+Report+Second+Quarter+Financial+Results+and+Provide+Corporate+Update+on+Aug+6%2C+2026/26826825.html Tue, 28 Jul 2026 16:01:00 -0400 ARCT O.41325150 http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26789622.html <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in Boston, Massachusetts: </p><p> <b>Canaccord Genuity 46th Annual Growth Conference (Fireside Chat)</b> </p><ul class="bwlistdisc"> <li> Tuesday, August 11, 2026 (12:00 p.m. ET) </li> </ul><p> Webcast link can be found under Investor Relations/Events section of Arcturus’ <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.arcturusrx.com%2Finvestor-calendar&amp;esheet=54573687&amp;newsitemid=20260720082379&amp;lan=en-US&amp;anchor=website&amp;index=1&amp;md5=3716ea82b5e0b0c54bfd2021e78b3c67" shape="rect">website</a>. </p><p> <b>About Arcturus</b> </p><p> Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26789622.html Mon, 20 Jul 2026 16:01:00 -0400 ARCT O.41325150 http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26789622.html <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in Boston, Massachusetts: </p><p> <b>Canaccord Genuity 46th Annual Growth Conference (Fireside Chat)</b> </p><ul class="bwlistdisc"> <li> Tuesday, August 11, 2026 (12:00 p.m. ET) </li> </ul><p> Webcast link can be found under Investor Relations/Events section of Arcturus’ <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.arcturusrx.com%2Finvestor-calendar&amp;esheet=54573687&amp;newsitemid=20260720082379&amp;lan=en-US&amp;anchor=website&amp;index=1&amp;md5=3716ea82b5e0b0c54bfd2021e78b3c67" shape="rect">website</a>. </p><p> <b>About Arcturus</b> </p><p> Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development http://www.streetinsider.com/Press+Releases/Arcturus+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26789622.html Mon, 20 Jul 2026 16:01:00 -0400 ARCT O.41325150 http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26789622.html <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in Boston, Massachusetts: </p><p> <b>Canaccord Genuity 46th Annual Growth Conference (Fireside Chat)</b> </p><ul class="bwlistdisc"> <li> Tuesday, August 11, 2026 (12:00 p.m. ET) </li> </ul><p> Webcast link can be found under Investor Relations/Events section of Arcturus’ <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.arcturusrx.com%2Finvestor-calendar&amp;esheet=54573687&amp;newsitemid=20260720082379&amp;lan=en-US&amp;anchor=website&amp;index=1&amp;md5=3716ea82b5e0b0c54bfd2021e78b3c67" shape="rect">website</a>. </p><p> <b>About Arcturus</b> </p><p> Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26789622.html Mon, 20 Jul 2026 16:01:00 -0400 ARCT O.41325150 http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26789622.html <p> SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in Boston, Massachusetts: </p><p> <b>Canaccord Genuity 46th Annual Growth Conference (Fireside Chat)</b> </p><ul class="bwlistdisc"> <li> Tuesday, August 11, 2026 (12:00 p.m. ET) </li> </ul><p> Webcast link can be found under Investor Relations/Events section of Arcturus’ <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.arcturusrx.com%2Finvestor-calendar&amp;esheet=54573687&amp;newsitemid=20260720082379&amp;lan=en-US&amp;anchor=website&amp;index=1&amp;md5=3716ea82b5e0b0c54bfd2021e78b3c67" shape="rect">website</a>. </p><p> <b>About Arcturus</b> </p><p> Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development http://www.streetinsider.com/Business+Wire/Arcturus+Therapeutics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26789622.html Mon, 20 Jul 2026 16:01:00 -0400 ARCT O.41325150 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arcturus+Therapeutics+++++For%3A+Jun+26/26723891.html si-local-file:///var/storage/secattach/20260702/26723891.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arcturus+Therapeutics+++++For%3A+Jun+26/26723891.html Thu, 02 Jul 2026 07:06:00 -0400 ARCT O.41325150 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arcturus+Therapeutics+++++For%3A+Jun+26/26723891.html si-local-file:///var/storage/secattach/20260702/26723891.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arcturus+Therapeutics+++++For%3A+Jun+26/26723891.html Thu, 02 Jul 2026 07:06:00 -0400 ARCT O.41325150